39.45
0.23%
-0.09
アフターアワーズ:
39.51
0.06
+0.15%
前日終値:
$39.54
開ける:
$39.42
24時間の取引高:
34,638
Relative Volume:
0.32
時価総額:
$549.28M
収益:
$138.20M
当期純損益:
$5.52M
株価収益率:
-23.91
EPS:
-1.65
ネットキャッシュフロー:
$9.86M
1週間 パフォーマンス:
+0.31%
1か月 パフォーマンス:
+5.17%
6か月 パフォーマンス:
-6.29%
1年 パフォーマンス:
+19.84%
Surmodics Inc Stock (SRDX) Company Profile
SRDX を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
39.45 | 549.28M | 138.20M | 5.52M | 9.86M | 0.38 |
ABT
Abbott Laboratories
|
118.77 | 206.00B | 41.22B | 5.77B | 6.49B | 3.29 |
SYK
Stryker Corp
|
392.15 | 149.49B | 21.97B | 3.59B | 3.21B | 9.33 |
BSX
Boston Scientific Corp
|
90.66 | 133.62B | 15.91B | 1.79B | 1.89B | 1.21 |
MDT
Medtronic Plc
|
86.54 | 110.97B | 33.00B | 4.29B | 5.50B | 3.27 |
EW
Edwards Lifesciences Corp
|
71.35 | 42.08B | 6.60B | 4.16B | 490.10M | 6.93 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-06-13 | アップグレード | Needham | Hold → Buy |
2023-02-13 | ダウングレード | Needham | Buy → Hold |
2020-07-23 | アップグレード | Needham | Hold → Buy |
2019-12-11 | ダウングレード | Needham | Buy → Hold |
2019-11-01 | ダウングレード | Lake Street | Buy → Hold |
2019-08-01 | 繰り返されました | Needham | Buy |
2019-05-02 | 繰り返されました | Lake Street | Buy |
2019-05-02 | 繰り返されました | Needham | Buy |
2019-02-21 | 繰り返されました | Needham | Buy |
2018-05-16 | 繰り返されました | Needham | Buy |
2018-03-01 | アップグレード | Sidoti | Neutral → Buy |
2018-02-28 | 繰り返されました | Lake Street | Buy |
2018-02-28 | 開始されました | Needham | Buy |
2017-07-14 | 開始されました | Lake Street | Buy |
2016-11-21 | ダウングレード | Barrington Research | Outperform → Mkt Perform |
2016-10-06 | ダウングレード | Sidoti | Buy → Neutral |
2016-05-03 | 繰り返されました | Barrington Research | Outperform |
2015-08-06 | 繰り返されました | Barrington Research | Outperform |
2015-03-27 | 開始されました | Dougherty & Company | Buy |
2014-02-25 | 開始されました | Laidlaw | Buy |
2013-08-01 | アップグレード | Feltl & Co. | Buy → Strong Buy |
2012-11-12 | 繰り返されました | Barrington Research | Outperform |
すべてを表示
Surmodics Inc (SRDX) 最新ニュース
Q2 Earnings Estimate for Surmodics Issued By Zacks Research - MarketBeat
Insider Sell: Timothy Arens Sells 7,009 Shares of Surmodics Inc (SRDX) - GuruFocus.com
FY2025 EPS Estimates for Surmodics Increased by Analyst - MarketBeat
SRDX (Surmodics) Cyclically Adjusted PS Ratio : 4.90 (As of Nov. 26, 2024) - GuruFocus.com
Principal Financial Group Inc. Purchases Shares of 30,696 Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Surmodics (NASDAQ:SRDX) Now Covered by StockNews.com - MarketBeat
SurModics Inc. Faces Legal Hurdles: Shareholder Lawsuits Threaten Merger and Financial Stability - Yahoo Finance
The Gory Details on SurModics's Double Miss - AOL
(SRDX) Long Term Investment Analysis - Stock Traders Daily
Surmodics Inc. (SRDX) reports earnings - Quartzy
Nashville InnoSurmodics adds to med-device portfolio with $39.9M acquisition of Vetex Medical - The Business Journals
Phocas Financial Corp. Invests $3.43 Million in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Surmodics (NASDAQ:SRDX) Coverage Initiated at StockNews.com - MarketBeat
Surmodics Q4 Earnings and Revenues Beat Estimates, Margin Down - MSN
SurModics (SRDX) is an Incredible Growth Stock: 3 Reasons Why - Yahoo Finance
Medical Device Coatings Market: Expected High CAGR with Key - openPR
Surmodics FY2026 EPS Forecast Lifted by Barrington Research - MarketBeat
Nisa Investment Advisors LLC Sells 67,336 Shares of Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Barrington Research Predicts Higher Earnings for Surmodics - MarketBeat
SurModics (SRDX) Reports Q4 Loss, Tops Revenue Estimates - MSN
48,591 Shares in Surmodics, Inc. (NASDAQ:SRDX) Bought by Olympiad Research LP - MarketBeat
Needham & Company LLC Reiterates "Hold" Rating for Surmodics (NASDAQ:SRDX) - MarketBeat
Surmodics revenue jumps 19% to USD 33.2M in Q4 2024 - Medical Buyer
Surmodics (NASDAQ:SRDX) Shares Cross Above Two Hundred Day Moving AverageHere's What Happened - MarketBeat
Surmodics Inc. Reports Q4 and FY 2024 Results - TipRanks
Morgan Stanley's Strategic Reduction in Surmodics Inc Holdings - GuruFocus.com
Surmodics reports Q4 EPS (13c), consensus (29c) - TipRanks
SurModics: Fiscal Q4 Earnings Snapshot - San Antonio Express-News
Surmodics Reports Fourth Quarter and Fiscal Year 2024 Financial Results - Business Wire
Surmodics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended September 30, 2024 - Marketscreener.com
Surmodics reports high success in limb ischemia study By Investing.com - Investing.com Australia
Surmodics Announces Early Results from PROWL Registry Study of Real-World Limb Ischemia Patients Treated with Pounce™ Thrombectomy System - BioSpace
Surmodics reports high success in limb ischemia study - Investing.com India
When (SRDX) Moves Investors should Listen - Stock Traders Daily
Surmodics (NASDAQ:SRDX) Now Covered by Analysts at StockNews.com - MarketBeat
Medical Coatings Market to Grow by USD 5.07 Billion from 2024-2028, Driven by Geriatric Population Growth and AI-Redefining the Market LandscapeTechnavio - Yahoo Finance Australia
Surmodics, Inc. (NASDAQ:SRDX) Shares Sold by Millennium Management LLC - MarketBeat
Surmodics (NASDAQ:SRDX) Earns Hold Rating from Analysts at StockNews.com - MarketBeat
Surmodics, Inc. to Post FY2025 Earnings of $0.13 Per Share, Zacks Research Forecasts (NASDAQ:SRDX) - MarketBeat
AQR Capital Management LLC Reduces Holdings in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Trend Tracker for (SRDX) - Stock Traders Daily
Algert Global LLC Makes New $577,000 Investment in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Surmodics (NASDAQ:SRDX) Coverage Initiated by Analysts at StockNews.com - MarketBeat
SRDX Stock Down Despite FDA Clearance for Pounce XL System - MSN
Biocompatible Coating Market to Reach $41.4 Billion, Globally, by 2033 at 12% CAGR: Allied Market Research - GlobeNewswire Inc.
Surmodics Inc (SRDX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):